TY - JOUR AU - Taugner, Julian AU - Käsmann, Lukas AU - Eze, Chukwuka AU - Dantes, Maurice AU - Roengvoraphoj, Olarn AU - Gennen, Kathrin AU - Karin, Monika AU - Petruknov, Oleg AU - Tufman, Amanda AU - Belka, Claus AU - Manapov, Farkhad PY - 2019 TI - Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy JF - Translational Lung Cancer Research; Vol 8, No 5 (October 29, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - Background: Stage III non-small cell lung cancer (NSCLC) represents a heterogeneous disease regarding principal patient- and tumor characteristics. A simple score may aid in personalizing multimodal therapy. Methods: The data of 99 consecutive patients with performance status ECOG 0–1 treated until the end of 2016 with multimodal approach for inoperable NSCLC (UICC 7th edition stage IIIA/B) were evaluated. Patient- and tumor-related factors were examined for their impact on overall survival. Factors showing a negative association with prognosis were then included in the score. Three subgroups with low, intermediate and high-risk score were defined. The results were then validated in the prospective cohort, which includes 45 patients. Results: Most Patients were treated with concurrent (78%) or sequential (11%) chemoradiotherapy. 53% received induction chemotherapy. Median survival for the entire cohort was 20.8 (range: 15.3–26.3) months. Age (P=0.020), gender (P=0.007), pack years (P=0.015), tumor-associated atelectasis (P=0.004) and histology (P=0.004) had a significant impact on overall survival and were scored with one point each. Twelve, 59 and 28 patients were defined to have a low (0–1 points), intermediate (2–3 points) and high-risk (4–5 points) score. Median survival, 1-, 2- and 3-year survival rates were not reached, 100%, 83% and 67% in the low, 22.9 months, 80%, 47% and 24% intermediate and 13.7 months, 57%, 25% and 18% high-risk patients, respectively (P Conclusions: The score demonstrated remarkable survival differences in inoperable stage III NSCLC patients with good performance status receiving multimodal therapy. UR - https://tlcr.amegroups.org/article/view/32494